Business
MDxHealth Announces Pricing of Initial Public Offering of ADSs in the United States
NEWS RELEASE - REGULATED INFORMATIONINSIDE INFORMATION4 NOVEMBER 2021, 13:00 CET MDxHealth Announces Pricing of Initial Public Offering of ADSsin the United
About this update from Mdxhealth Sa
[{"type":"text","content":" NEWS RELEASE - REGULATED INFORMATIONINSIDE INFORMATION4 NOVEMBER 2021, 13:00 CET MDxHealth Announces Pricing of Initial Public Offering of ADSsin the United States IRVINE, CA, and HERSTAL, BELGIUM – November 4, 2021 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (\"MDxHealth\" or the \"Company\"), a commercial-stage precision diagnostics company, today announced the pricing of its initial public offering in the United States (the \"Offering\") of 3,750,000 American Depositary Shares (each representing 10 ordinary shares of the Company with no nominal value per share) (\"ADSs\") at a price to the public of USD 12.00 per ADS1 for total gross proceeds of USD 45.0 million2 before deducting underwriting discounts and commissions and estimated offering expenses. In connection with the Offering, MDxHealth has granted the underwriters a 30-day option to purchase additional ordinary shares, which may be in the form of ADSs, on the same terms and conditions, representing up to 15% of the total number of ordinary shares (as the case may be, in the form of ADSs) offered in the Offering. The closing of the Offering is expected to occur on November 8, 2021, subject to the satisfaction of customary closing conditions. MDxHealth’s ordinary shares are currently listed on Euronext Brussels under the symbol “MDXH”. The ADSs are expected to begin trading on the NASDAQ Capital Market on November 4, 2021 under the symbol “MDXH”. Piper Sandler and Oppenheimer & Co. Inc. are acting as lead book-running managers, BTIG is acting as a lead manager, and KBC Securities USA is acting as a co-manager for the Offering. A registration statement on Form F-1 relating to and describing the terms of the Offering was filed with the U.S. Securities and Exchange Commission and was declared effective on November 3, 2021. The ADSs may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or a solicitation of an offer to buy securities of the Company nor shall there be any offer, solicitation or sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification or publication of an offering prospectus under the securities laws of any such state or jurisdiction. A...